Skip to main content
    L

    Lineage Cell Therapeutics Inc (LCTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.80
    -0.11 (-12.45%)

    Market Cap: $231.35M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Lineage Cell Therapeutics Inc (LCTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Lineage Cell Therapeutics reported revenue of $14.56M for the fiscal year ended Dec 31, 2025, up 53.2% from the year before. That year, net income was -$63.37M with a net margin of -435.3%, operating cash flow was -$18.92M and free cash flow was -$19.44M. The quarter ended Sep 30, 2026 had revenue of $1.43M and net income of $4.23M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $5.92M, a compound annual rate of 10.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$14.56M+53.2%99.0%-251.6%-435.3%
    Dec 2024$9.50M+6.2%96.5%-226.1%-195.6%
    Dec 2023$8.95M-39.2%92.5%-276.5%-240.1%
    Dec 2022$14.70M+238.7%95.0%-153.2%-179.2%
    Dec 2021$4.34M+137.7%67.2%-1133.6%-996.8%
    Dec 2020$1.83M-48.1%78.9%-1448.4%-1132.8%
    Dec 2019$3.52M-29.5%88.3%-1106.0%-336.5%
    Dec 2018$4.99M+44.2%93.9%-837.9%-937.9%
    Dec 2017$3.46M-41.6%95.1%-1125.0%-673.5%
    Dec 2016$5.92MN/A94.0%-995.6%314.4%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$14.56M$9.50M$8.95M$14.70M$4.34M$1.83M$3.52M$4.99M$3.46M$5.92M
    Cost of revenue$146.00K$334.00K$671.00K$728.00K$1.43M$385.00K$412.00K$302.00K$168.00K$358.00K
    Gross profit$14.41M$9.16M$8.27M$13.97M$2.92M$1.44M$3.10M$4.69M$3.29M$5.57M
    Research and development$17.73M$12.47M$15.71M$13.99M$33.91M$12.32M$17.95M$21.75M$24.02M$36.11M
    Operating income-$36.62M-$21.48M-$24.73M-$22.52M-$49.21M-$26.45M-$38.88M-$41.80M-$38.90M-$58.97M
    Net income-$63.37M-$18.58M-$21.48M-$26.35M-$43.27M-$20.68M-$11.83M-$46.78M-$23.29M$18.62M
    EBITDAN/A-$19.69M-$24.22MN/A-$43.13M-$21.05M-$26.34MN/AN/A-$19.80M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.43M$1.07M$1.73M$6.61M$3.68M$2.77M$1.50M$2.87M$3.78M$1.41M$1.44M$2.09M
    Gross profit$1.43M$1.07M$1.73M$6.54M$3.68M$2.73M$1.47M$2.71M$3.74M$1.36M$1.35M$1.83M
    Operating income-$7.31M-$8.92M-$7.59M-$6.55M-$3.79M-$19.78M-$6.50M-$5.11M-$3.84M-$5.87M-$6.66M-$6.36M
    Net income$4.23M$1.54M-$4.79M$892.00K-$29.75M-$30.36M-$4.14M-$3.25M-$3.00M-$5.77M-$6.56M-$4.71M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $37.00K by $40.75M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$112.58M$113.22M$101.02M$123.66M$174.54M$107.95M$125.48M$101.66M$173.24M$142.57M
    Current assets$59.16M$51.00M$38.44M$60.00M$111.55M$44.00M$57.52M$36.36M$42.62M$25.65M
    Cash and equivalents$40.79M$45.79M$35.44M$11.36M$55.74M$32.59M$9.50M$23.59M$36.84M$22.09M
    Total liabilities$69.24M$36.21M$39.00M$51.73M$83.65M$12.82M$14.23M$9.41M$8.98M$12.06M
    Short-term debt$37.00K$55.00K$52.00K$36.00K$831.00K$16.00K$1.22M$70.00K$364.00K$1.13M
    Long-term debtN/AN/AN/AN/AN/AN/AN/A$104.00K$18.00K$1.15M
    Shareholder equity$44.55M$78.38M$63.42M$73.34M$92.22M$96.20M$112.96M$93.84M$162.64M$117.93M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$100.11M$106.22M$109.53M$112.58M$89.64M$90.80M$111.75M$113.22M$96.59M$102.80M$108.48M$101.02M
    Total liabilities$34.17M$46.42M$56.84M$69.24M$68.84M$43.69M$34.10M$36.21M$31.80M$35.93M$37.49M$39.00M
    Cash and equivalents$26.50M$37.35M$35.94M$40.79M$40.46M$42.27M$47.89M$45.79M$27.75M$29.62M$43.58M$35.44M
    Shareholder equity$67.06M$60.92M$53.88M$44.55M$22.04M$48.38M$79.03M$78.38M$66.19M$68.30M$72.40M$63.42M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$18.92M-$23.09M-$28.57M$1.06M-$23.56M-$19.75M-$31.95M-$30.88M-$30.52M-$42.33M
    Capital expenditures$522.00K$565.00K$674.00K$413.00K$340.00K$64.00K$440.00K$1.42M$1.33M$2.53M
    Free cash flow-$19.44M-$23.66M-$29.24M$646.00K-$23.90M-$19.82M-$32.39M-$32.30M-$31.84M-$44.85M
    Dividends paidN/AN/A$37.00KN/A$7.24M$25.15M$40.00K$34.41M$454.00KN/A
    Share repurchasesN/AN/A$0$106.00KN/AN/AN/AN/A$0N/A
    Investing cash flow-$13.46M-$2.31M$46.45M-$46.16M$9.74M$13.04M$16.96M$11.82M-$10.22M-$10.89M
    Financing cash flow$26.95M$35.86M$6.42M$1.63M$36.93M$29.86M$617.00K$5.77M$55.39M$32.78M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.62M-$7.24M-$8.08M-$4.88M-$3.62M-$5.54M-$4.89M-$6.35M-$5.79M-$5.18M-$5.78M-$6.02M
    Capital expenditures$74.00K$108.00K$55.00K$399.00K$12.00K$14.00K$97.00K$365.00K$112.00K$50.00K$38.00K$91.00K
    Free cash flow-$5.69M-$7.35M-$8.13M-$5.28M-$3.63M-$5.55M-$4.98M-$6.71M-$5.90M-$5.23M-$5.82M-$6.11M
    Last 12 quarters

    Frequently Asked Questions About LCTX

    What is Lineage Cell Therapeutics' annual revenue?

    Lineage Cell Therapeutics reported revenue of $14.56M for the fiscal year ended Dec 31, 2025.

    How fast is Lineage Cell Therapeutics' revenue growing?

    Revenue was up 53.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -0.3%.

    Is Lineage Cell Therapeutics profitable?

    No. Lineage Cell Therapeutics reported net income of -$63.37M for the fiscal year ended Dec 31, 2025, with a net margin of -435.3%.

    How much free cash flow does LCTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$18.92M minus capital expenditures of $522.00K produced free cash flow of -$19.44M.

    How much debt does Lineage Cell Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $37.00K and cash and equivalents of $40.79M.